Spyre CMO exercises options, sells 8,334 shares

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.

The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,334 shares ($502K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Sloan Sheldon

Role Chief Medical Officer

Sold 8,334 shs ($731K)

Approx. gross sale proceeds $731K

Approx. exercise cost $229K

Approx. pre-tax spread $502K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	8,334	$0.00	$0.00
Exercise	Common Stock	8,334	$27.46	$229K
Sale	Common Stock	6,500	$87.52	$569K
Sale	Common Stock	1,834	$88.34	$162K

Holdings After Transaction: Stock Option (Right to Buy) — 305,000 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (4)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Shares sold: 8,334 shares Sale price (weighted average): $87.52/share and $88.34/share Sale price ranges: $87.03–$87.99 and $88.03–$88.95 +5 more

8 metrics

Shares sold 8,334 shares Common stock sold in open-market transactions on July 1, 2026

Sale price (weighted average) $87.52/share and $88.34/share Two reported weighted average sale prices for common stock

Sale price ranges $87.03–$87.99 and $88.03–$88.95 Price ranges for multiple sale transactions

Option exercise price $27.46/share Exercise price for 8,334 options converted into common stock

Remaining stock options 305,000 options Options to purchase common stock held after transactions

Total option grant size 400,000 shares Underlying shares for the CMO’s stock option award

Option expiration date October 1, 2034 Expiration for the reported stock option grant

10b5-1 plan adoption date June 20, 2025 Date the pre-arranged trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vested and became exercisable, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) ... represents the right to purchase 400,000 shares of the Issuer's common stock..."

vested and became exercisable financial

"one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting..."

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 09:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sloan Sheldon

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		M(1)		8,334	A	$27.46	8,334	D
Common Stock	07/01/2026		S(1)		6,500	D	$87.52(2)	1,834	D
Common Stock	07/01/2026		S(1)		1,834	D	$88.34(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.46	07/01/2026		M(1)			8,334	(4)	10/01/2034	Common Stock	8,334	$0	305,000	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)